Risultati della ricerca - Saremi, Aramesh

Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT) di Saremi, Aramesh, Bahn, Gideon, Reaven, Peter D.

Testo Testo Testo

A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT) di Saremi, Aramesh, Bahn, Gideon D., Reaven, Peter D.

Testo Testo Testo

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial di Giorgino, Francesco, Shaunik, Alka, Liu, Minzhi, Saremi, Aramesh

Testo Testo Testo

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT) di Koska, Juraj, Saremi, Aramesh, Bahn, Gideon, Yamashita, Shizuya, Reaven, Peter D.

Testo Testo Testo

Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration... di Gautier, Thibault, Silwal, Rupesh, Saremi, Aramesh, Boss, Anders, Breton, Marc D.

Testo Testo Testo

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L di Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Testo Testo Testo

Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L di Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Testo Testo Testo

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L di Blonde, Lawrence, Berard, Lori, Saremi, Aramesh, Huang, Yao, Aroda, Vanita R., Raccah, Denis

Testo Testo Testo

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial di Saremi, Aramesh, Schwenke, Dawn C., Bahn, Gideon, Ge, Ling, Emanuele, Nicholas, Reaven, Peter D.

Testo Testo Testo

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study di Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D.

Testo Testo Testo

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study di Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco

Testo Testo Testo

Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT) di Saremi, Aramesh, Moritz, Thomas E., Anderson, Robert J., Abraira, Carlos, Duckworth, William C., Reaven, Peter D.

Testo Testo Testo

Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance di Hu, Xia, Reaven, Peter D., Saremi, Aramesh, Liu, Ninghao, Abbasi, Mohammad Ali, Liu, Huan, Migrino, Raymond Q.

Testo Testo Testo

Association Between IL-6 and the extent of Coronary Atherosclerosis in The Veterans Affairs Diabetes Trial (VADT) di Saremi, Aramesh, Anderson, Robert J., Luo, Ping, Moritz, Thomas E., Schwenke, Dawn C., Allison, Mathew, Reaven, Peter D.

Testo Testo Testo

Quantification of LVEF≤35% misclassification by 2D-echocardiography as compared to cardiac magnetic resonance in coronary artery disease: implications for AICD therapy di Parrington, Diane J, Saremi, Aramesh, Girotra, Sudhakar V, Dev, Sandesh, Oh, Charles, Scott, Cynthia L, Migrino, Raymond Q

Testo Testo

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes di Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D.

Testo Testo Testo

Hepatic Fat and Inflammation in Type 2 Diabetes di Saremi, Aramesh, Allison, Matthew, Ditomasso, Dominic, Ge, Ling, Anderson, Robert, Moritz, Tom E., Duckworth, William, Abraira, Carlos, Reaven, Peter D.

Testo Testo Testo

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... di Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.

Testo Testo Testo

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Explorat... di Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio

Testo Testo Testo

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors di Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.

Testo Testo Testo